FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:549-559 August 10, 2006 Number 6 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Kent, D. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established.

Methods We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke.

Results The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients (13.1 percent) receiving placebo had a fatal or nonfatal stroke (5-year absolute reduction in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03; unadjusted P=0.05). The atorvastatin group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year absolute reduction in the risk of major cardiovascular events was 3.5 percent (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002). The overall mortality rate was similar, with 216 deaths in the atorvastatin group and 211 deaths in the placebo group (P=0.98), as were the rates of serious adverse events. Elevated liver enzyme values were more common in patients taking atorvastatin.

Conclusions In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke. (ClinicalTrials.gov number, NCT00147602 [ClinicalTrials.gov] .)

Source Information

Pierre Amarenco, M.D. (Denis Diderot University, Paris), Julien Bogousslavsky, M.D. (University of Lausanne, Lausanne, Switzerland), Alfred Callahan, III, M.D. (Neurologic Consultants, Nashville), Larry B. Goldstein, M.D. (Duke University Medical Center, Durham, N.C.), Michael Hennerici, M.D., Ph.D. (Universitat Heidelberg, Mannheim, Germany), Amy E. Rudolph, Ph.D. (Pfizer, New York), Henrik Sillesen, M.D., D.M.Sc. (University of Copenhagen, Copenhagen), Lisa Simunovic, M.S. (Pfizer, New York), Michael Szarek, M.S. (Pfizer, New York), K.M.A. Welch, M.B., Ch.B., (Rosalind Franklin University of Medicine and Science, North Chicago), and Justin A. Zivin, M.D., Ph.D. (University of California, San Diego) assume full responsibility for the overall content and integrity of the article.

Address reprint requests to Dr. Welch at the Rosalind Franklin University of Medicine and Science, 3333 Green Bay Rd., North Chicago, IL 60064, or at michael.welch{at}rosalindfranklin.edu.

Full Text of this Article

Related Letters:

Statin Therapy after Stroke or Transient Ischemic Attack
Cohen J. S., East J. E., Elkind M. S.V., Khan N. A., Mascitelli L., Pezzetta F., Welch K.M.A., the SPARCL Investigators , Kent D.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:2368-2371, Nov 30, 2006. Correspondence

This article has been cited by other articles:

• Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., Moher, D. (2009). Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia. ANN INTERN MED 151: 622-630 [Abstract] [Full Text]  
• Willey, J. Z., Xu, Q., Boden-Albala, B., Paik, M. C., Moon, Y. P., Sacco, R. L., Elkind, M. S. V. (2009). Lipid Profile Components and Risk of Ischemic Stroke: The Northern Manhattan Study (NOMAS). Arch Neurol 66: 1400-1406 [Abstract] [Full Text]  
• Goldstein, L. B., Amarenco, P., Zivin, J., Messig, M., Altafullah, I., Callahan, A., Hennerici, M., MacLeod, M. J., Sillesen, H., Zweifler, R., Michael, K., Welch, A., on behalf of the SPARCL Investigators, (2009). Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke 40: 3526-3531 [Abstract] [Full Text]  
• Rabinstein, A. A. (2009). Statins Prevent Stroke Recurrences... But Can They Improve Stroke Outcome?. Stroke 40: 3413-3414 [Full Text]  
• Paraskevas, K. I., Mikhailidis, D. P., Bell, P. R.F. (2009). The GALA Trial: Will It Influence Clinical Practice?. VASC ENDOVASCULAR SURG 43: 429-432 [Abstract]  
• Landau, W., Strupp, M., Bianchi, M. T., Westover, B., Chaturvedi FAHA, FAAN, S. (2009). EFFECT OF ATORVASTATIN IN ELDERLY PATIENTS WITH A RECENT STROKE OR TRANSIENT ISCHEMIC ATTACK. Neurology 73: 817-819 [Full Text]  
• Giannakopoulos, B., Krilis, S. A. (2009). How I treat the antiphospholipid syndrome. Blood 114: 2020-2030 [Abstract] [Full Text]  
• Smith, E. E., Liang, L., Hernandez, A., Reeves, M. J., Cannon, C. P., Fonarow, G. C., Schwamm, L. H. (2009). Influence of stroke subtype on quality of care in the Get With The Guidelines-Stroke Program. Neurology 73: 709-716 [Abstract] [Full Text]  
• Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., Moher, D. (2009). Systematic Review: Comparative Effectiveness and Harms of Combinations of Lipid-Modifying Agents and High-Dose Statin Monotherapy. ANN INTERN MED 0: 0000605-200911030-00144v1-E-144 [Abstract] [Full Text]  
• Elewa, H. F., Kozak, A., El-Remessy, A. B., Frye, R. F., Johnson, M. H., Ergul, A., Fagan, S. C. (2009). Early Atorvastatin Reduces Hemorrhage after Acute Cerebral Ischemia in Diabetic Rats. J. Pharmacol. Exp. Ther. 330: 532-540 [Abstract] [Full Text]  
• Prinz, V., Endres, M. (2009). The Acute (Cerebro)Vascular Effects of Statins. Anesth. Analg. 109: 572-584 [Abstract] [Full Text]  
• Lasserson, D S (2009). Initial management of suspected transient cerebral ischaemia and stroke in primary care: implications of recent research. Postgrad. Med. J. 85: 422-427 [Abstract] [Full Text]  
• Castilla-Guerra, L., del Carmen Fernandez-Moreno, M., Jimenez-Hernandez, M. D., Chaturvedi, S. (2009). EFFECT OF ATORVASTATIN IN ELDERLY PATIENTS WITH A RECENT STROKE OR TRANSIENT ISCHEMIC ATTACK. Neurology 73: 248-249 [Full Text]  
• Mascitelli, L., Pezzetta, F., Goldstein, M. R., Chaturvedi, S. (2009). EFFECT OF ATORVASTATIN IN ELDERLY PATIENTS WITH A RECENT STROKE OR TRANSIENT ISCHEMIC ATTACK. Neurology 73: 249-250 [Full Text]  
• Heck, D (2009). Incidence and time course of carotid in-stent restenosis in a consecutive series of 295 patients. Journal of NeuroInterventional Surgery 0: jnis.2009.000349v1-jnis.2009.000349 [Abstract] [Full Text]  
• Leker, R. R., Khoury, S. T., Rafaeli, G., Shwartz, R., Eichel, R., Tanne, D., on behalf of the NASIS Investigators, (2009). Prior Use of Statins Improves Outcome in Patients With Intracerebral Hemorrhage: Prospective Data from the National Acute Stroke Israeli Surveys (NASIS). Stroke 40: 2581-2584 [Abstract] [Full Text]  
• Amarenco, P., Goldstein, L. B., Messig, M., O'Neill, B. J., Callahan, A. III, Sillesen, H., Hennerici, M. G., Zivin, J. A., Welch, K.M.A., on behalf of the SPARCL Investigators, (2009). Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke 40: 2486-2492 [Abstract] [Full Text]  
• Rojas-Fernandez, C. H, Moorhouse, P. (2009). Current Concepts in Vascular Cognitive Impairment and Pharmacotherapeutic Implications. The Annals of Pharmacotherapy 43: 1310-1323 [Abstract] [Full Text]  
• Diener, H.-C., Weimar, C. (2009). Update of secondary stroke prevention. Nephrol Dial Transplant 24: 1718-1724 [Full Text]  
• Turan, T. N., Derdeyn, C. P., Fiorella, D., Chimowitz, M. I. (2009). Treatment of Atherosclerotic Intracranial Arterial Stenosis. Stroke 40: 2257-2261 [Full Text]  
• Milionis, H. J., Giannopoulos, S., Kosmidou, M., Panoulas, V., Manios, E., Kyritsis, A. P., Elisaf, M. S., Vemmos, K. (2009). Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival. Neurology 72: 1816-1822 [Abstract] [Full Text]  
• Tong, D. C. (2009). Statins and stroke. Neurology 72: e112-e113 [Full Text]  
• Di Tullio, M. R., Russo, C., Jin, Z., Sacco, R. L., Mohr, J.P., Homma, S., for the Patent Foramen Ovale in Cryptogenic Stroke, (2009). Aortic Arch Plaques and Risk of Recurrent Stroke and Death. Circulation 119: 2376-2382 [Abstract] [Full Text]  
• Niessen, J., Jedlitschky, G., Grube, M., Bien, S., Schwertz, H., Ohtsuki, S., Kawakami, H., Kamiie, J., Oswald, S., Starke, K., Strobel, U., Siegmund, W., Rosskopf, D., Greinacher, A., Terasaki, T., Kroemer, H. K. (2009). Human Platelets Express Organic Anion-Transporting Peptide 2B1, an Uptake Transporter for Atorvastatin. Drug Metab. Dispos. 37: 1129-1137 [Abstract] [Full Text]  
• Meier, N., Nedeltchev, K., Brekenfeld, C., Galimanis, A., Fischer, U., Findling, O., Remonda, L., Schroth, G., Mattle, H. P., Arnold, M. (2009). Prior Statin Use, Intracranial Hemorrhage, and Outcome After Intra-Arterial Thrombolysis for Acute Ischemic Stroke. Stroke 40: 1729-1737 [Abstract] [Full Text]  
• Kim, B. J., Lee, S.-H., Ryu, W.-S., Kang, B. S., Kim, C. K., Yoon, B.-W. (2009). Low Level of Low-Density Lipoprotein Cholesterol Increases Hemorrhagic Transformation in Large Artery Atherothrombosis but Not in Cardioembolism. Stroke 40: 1627-1632 [Abstract] [Full Text]  
• Lavallee, P. C., Labreuche, J., Gongora-Rivera, F., Jaramillo, A., Brenner, D., Klein, I. F, Touboul, P.-J., Vicaut, E., Amarenco, P., on behalf of the Lacunar-B.I.C.H.A.T. Investigator, (2009). Placebo-Controlled Trial of High-Dose Atorvastatin in Patients With Severe Cerebral Small Vessel Disease. Stroke 40: 1721-1728 [Abstract] [Full Text]  
• Goldstein, L. B. (2009). The Complex Relationship Between Cholesterol and Brain Hemorrhage. Circulation 119: 2131-2133 [Full Text]  
• Noda, H., Iso, H., Irie, F., Sairenchi, T., Ohtaka, E., Doi, M., Izumi, Y., Ohta, H. (2009). Low-Density Lipoprotein Cholesterol Concentrations and Death Due to Intraparenchymal Hemorrhage: The Ibaraki Prefectural Health Study. Circulation 119: 2136-2145 [Abstract] [Full Text]  
• Vergouwen, M. D.I., Vermeulen, M., Roos, Y. B.W.E.M., Goldstein, L. B. (2009). HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDY. Neurology 72: 1447-1448 [Full Text]  
• Goldstein, M. R., Mascitelli, L., Pezzetta, F., Goldstein, L. B. (2009). HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDY. Neurology 72: 1448-1449 [Full Text]  
• Raine, R., Wong, W., Ambler, G., Hardoon, S., Petersen, I., Morris, R., Bartley, M., Blane, D. (2009). Sociodemographic variations in the contribution of secondary drug prevention to stroke survival at middle and older ages: cohort study. BMJ 338: b1279-b1279 [Abstract] [Full Text]  
• Lanzino, G., Rabinstein, A. A., Brown, R. D. Jr (2009). Treatment of Carotid Artery Stenosis: Medical Therapy, Surgery, or Stenting?. Mayo Clin Proc. 84: 362-368 [Abstract] [Full Text]  
• Saposnik, G., Goodman, S. G., Leiter, L. A., Yan, R. T., Fitchett, D. H., Bayer, N. H., Casanova, A., Langer, A., Yan, A. T., for the Vascular Protection (VP), , Guidelines-Oriented Approach to Lipid-Lowering (GO, , on behalf of the Stroke Outcome Research Canada (S, (2009). Applying the Evidence: Do Patients With Stroke, Coronary Artery Disease, or Both Achieve Similar Treatment Goals?. Stroke 40: 1417-1424 [Abstract] [Full Text]  
• Amarenco, P., Benavente, O., Goldstein, L. B., Callahan, A. III, Sillesen, H., Hennerici, M. G., Gilbert, S., Rudolph, A. E., Simunovic, L., Zivin, J. A., Welch, K. M. A., on behalf of the SPARCL Investigators, (2009). Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes. Stroke 40: 1405-1409 [Abstract] [Full Text]  
• Putaala, J., Metso, A. J., Metso, T. M., Konkola, N., Kraemer, Y., Haapaniemi, E., Kaste, M., Tatlisumak, T. (2009). Analysis of 1008 Consecutive Patients Aged 15 to 49 With First-Ever Ischemic Stroke: The Helsinki Young Stroke Registry. Stroke 40: 1195-1203 [Abstract] [Full Text]  
• Josephson, C. B, Salman, R. A.-S., Phillips, S. J (2009). An episode of transient neurological symptoms. BMJ 338: b616-b616 [Full Text]  
• Coull, B. M., Johnston, S. C. (2009). Statins: Not just for the young or the faint of heart. Neurology 72: 684-685 [Full Text]  
• Chaturvedi, S., Zivin, J., Breazna, A., Amarenco, P., Callahan, A., Goldstein, L. B., Hennerici, M., Sillesen, H., Rudolph, A., Welch, M. A., For the SPARCL Investigators, (2009). Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology 72: 688-694 [Abstract] [Full Text]  
• Sacco, S., Marini, C., Toni, D., Olivieri, L., Carolei, A. (2009). Incidence and 10-Year Survival of Intracerebral Hemorrhage in a Population-Based Registry. Stroke 40: 394-399 [Abstract] [Full Text]  
• Samuelson, R. M., Levy, E. I., Siddiqui, A. H., Hopkins, L. N. (2009). The Cost of Stroke Prevention. Stroke 40: e41-e42 [Full Text]  
• Gonzalez-Hernandez, A., Fabre-Pi, O., Lopez-Fernandez, J. C. (2009). Recurrent Events in Transient Ischemic Attack and Minor Stroke. Stroke 40: e33-e33 [Full Text]  
• Robinson, J. G., Wang, S., Smith, B. J., Jacobson, T. A. (2009). Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.. J Am Coll Cardiol 53: 316-322 [Abstract] [Full Text]  
• Dore, D. D., Lapane, K. L., Trivedi, A. N., Mor, V., Weinstock, M. A. (2009). Association Between Statin Use and Risk for Keratinocyte Carcinoma in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. ANN INTERN MED 150: 9-18 [Abstract] [Full Text]  
• Gattellari, M., Worthington, J., Zwar, N. (2009). Warfarin: An Inconvenient Truth. Stroke 40: 5-7 [Full Text]  
• Adams, H. P. Jr (2009). Secondary Prevention of Atherothrombotic Events After Ischemic Stroke. Mayo Clin Proc. 84: 43-51 [Abstract] [Full Text]  
• Sillesen, H., Amarenco, P., Hennerici, M. G., Callahan, A., Goldstein, L. B., Zivin, J., Messig, M., Welch, K. M., on Behalf of the SPARCL Investigators, (2008). Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis: A Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke 39: 3297-3302 [Abstract] [Full Text]  
• Ridker, P. M, Danielson, E., Fonseca, F. A.H., Genest, J., Gotto, A. M. Jr., Kastelein, J. J.P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., Glynn, R. J., the JUPITER Study Group, (2008). Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. NEJM 359: 2195-2207 [Abstract] [Full Text]  
• Mascitelli, L., Pezzetta, F., Goldstein, M. R. (2008). Hemorrhagic Stroke in the SPARCL Study. Stroke 39: e180-e180 [Full Text]  
• Goldstein, L. B. (2008). Response to Letter by Mascitelli et al. Stroke 39: e181-e181 [Full Text]  
• Talelli, P., Greenwood, R. J. (2008). Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?. Ther Adv Cardiovasc Dis 2: 387-405 [Abstract]  
• Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., Kawamori, R. (2008). Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93: 3671-3689 [Abstract] [Full Text]  
• Bath, P. M.W., Geeganage, C., Gray, L. J., Collier, T., Pocock, S. (2008). Use of Ordinal Outcomes in Vascular Prevention Trials: Comparison With Binary Outcomes in Published Trials * Supplemental Appendix I: Statistical Tests Compared * Supplemental Appendix II: Supplementary Analyses * Supplemental Appendix III: Results. Stroke 39: 2817-2823 [Abstract] [Full Text]  
• Sander, D., Sander, K., Poppert, H. (2008). Review: Stroke in type 2 diabetes. British Journal of Diabetes & Vascular Disease 8: 222-229 [Abstract]  
• Newman, C. B, Szarek, M., Colhoun, H. M, Betteridge, D J., Durrington, P. N, Hitman, G. A, Neil, H A. W, Demicco, D. A, Auster, S., Fuller, J. H (2008). The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes and Vascular Disease Research 5: 177-183 [Abstract]  
• Coutts, S. B., Hill, M. D., Campos, C. R., Choi, Y. B., Subramaniam, S., Kosior, J. C., Demchuk, A. M., for the VISION study group, (2008). Recurrent Events in Transient Ischemic Attack and Minor Stroke: What Events Are Happening and to Which Patients?. Stroke 39: 2461-2466 [Abstract] [Full Text]  
• Goldstein, L. B., Amarenco, P., LaMonte, M., Gilbert, S., Messig, M., Callahan, A., Hennerici, M., Sillesen, H., Welch, K. M. A., on behalf of the SPARCL Investigators, (2008). Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women: Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 39: 2444-2448 [Abstract] [Full Text]  
• Romero, J. R., Morris, J., Pikula, A. (2008). Review: Stroke prevention: modifying risk factors. Ther Adv Cardiovasc Dis 2: 287-303 [Abstract]  
• O'Keefe, J. H., Bybee, K. A., Lavie, C. J. (2008). Intensive Lipid Intervention in the Post-ENHANCE Era. Mayo Clin Proc. 83: 867-869 [Full Text]  
• Caplan, L. R. (2008). A 70-Year-Old Man With a Transient Ischemic Attack: Review of Internal Carotid Artery Stenosis. JAMA 300: 81-90 [Abstract] [Full Text]  
• Amarenco, P., Steg, P. G. (2008). Stroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke prevention. Eur Heart J 29: 1605-1607 [Full Text]  
• FitzMaurice, E., Wendell, L., Snider, R., Schwab, K., Chanderraj, R., Kinnecom, C., Nandigam, K., Rost, N. S., Viswanathan, A., Rosand, J., Greenberg, S. M., Smith, E. E. (2008). Effect of Statins on Intracerebral Hemorrhage Outcome and Recurrence. Stroke 39: 2151-2154 [Abstract] [Full Text]  
• Tanaka, K., Ishikawa, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Saito, Y., Matsuzawa, Y., Sasaki, J., Oikawa, S., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shimada, K., Shirato, K., for the JELIS Investigators, Japan, (2008). Reduction in the Recurrence of Stroke by Eicosapentaenoic Acid for Hypercholesterolemic Patients: Subanalysis of the JELIS Trial. Stroke 39: 2052-2058 [Abstract] [Full Text]  
• Squizzato, A., Dentali, F., Romualdi, E., Ageno, W. (2008). Statins and Secondary Prevention of Ischemic and Hemorrhagic Stroke. Stroke 39: e113-e113 [Full Text]  
• Tinetti, M. E. (2008). Over-the-Counter Sales of Statins and Other Drugs for Asymptomatic Conditions. NEJM 358: 2728-2732 [Full Text]  
• Jacobs, B. S., Greenberg, S. M. (2008). Statins, low cholesterol, and hemorrhagic stroke: An uncertain triangle. Neurology 70: 2355-2356 [Full Text]  
• Goldstein, L. B., Amarenco, P., Szarek, M., Callahan, A. III, Hennerici, M., Sillesen, H., Zivin, J. A., Welch, K.M.A., On behalf of the SPARCL Investigators, (2008). Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 70: 2364-2370 [Abstract] [Full Text]  
• Rodriguez-Yanez, M., Agulla, J., Rodriguez-Gonzalez, R., Sobrino, T., Castillo, J. (2008). Review: Statins and stroke. Ther Adv Cardiovasc Dis 2: 157-166 [Abstract]  
• Sudlow, C (2008). Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management. PN 8: 141-157 [Abstract] [Full Text]  
• Shah, S. J., Waters, D. D., Barter, P., Kastelein, J. J.P., Shepherd, J., Wenger, N. K., DeMicco, D. A., Breazna, A., LaRosa, J. C. (2008). Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. J Am Coll Cardiol 51: 1938-1943 [Abstract] [Full Text]  
• Mascitelli, L., Pezzetta, F., Castillo, J., Blanco, M., Davalos, A., de Compostela, S. (2008). STATIN TREATMENT WITHDRAWAL IN ISCHEMIC STROKE: A CONTROLLED RANDOMIZED STUDY. Neurology 70: 1720-1721 [Full Text]  
• Arvanitakis, Z., Schneider, J. A., Wilson, R. S., Bienias, J. L., Kelly, J. F., Evans, D. A., Bennett, D. A. (2008). Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70: 1795-1802 [Abstract] [Full Text]  
• Fedoruk, L. M., Wang, H., Conaway, M. R., Kron, I. L., Johnston, K. C. (2008). Statin Therapy Improves Outcomes After Valvular Heart Surgery. Ann. Thorac. Surg. 85: 1521-1526 [Abstract] [Full Text]  
• Adams, R. J., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., Johnston, S. C., Katzan, I., Kelly-Hayes, M., Kenton, E. J., Marks, M., Sacco, R. L., Schwamm, L. H. (2008). Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke 39: 1647-1652 [Full Text]  
• Golomb, B. A., Dimsdale, J. E., White, H. L., Ritchie, J. B., Criqui, M. H. (2008). Reduction in Blood Pressure With Statins: Results From the UCSD Statin Study, a Randomized Trial. Arch Intern Med 168: 721-727 [Abstract] [Full Text]  
• Betteridge, D. J., DeFronzo, R. A., Chilton, R. J. (2008). PROactive: time for a critical appraisal. Eur Heart J 29: 969-983 [Abstract] [Full Text]  
• Vernooij, M. W., van der Lugt, A., Ikram, M. A., Wielopolski, P. A., Niessen, W. J., Hofman, A., Krestin, G. P., Breteler, M.M.B. (2008). Prevalence and risk factors of cerebral microbleeds: The Rotterdam Scan Study. Neurology 70: 1208-1214 [Abstract] [Full Text]  
• Levy, E. I., Mocco, J., Samuelson, R. M., Ecker, R. D., Jahromi, B. S., Hopkins, L. N. (2008). Optimal treatment of carotid artery disease.. J Am Coll Cardiol 51: 979-985 [Abstract] [Full Text]  
• Nassief, A., Marsh, J. D. (2008). Statin Therapy for Stroke Prevention. Stroke 39: 1042-1048 [Abstract] [Full Text]  
• Mascitelli, L., Vos, E. (2008). Analyzing the Results of the Treating to New Targets Study. ANN INTERN MED 148: 321-322 [Full Text]  
• Vergouwen, M. D.I., de Haan, R. J., Vermeulen, M., Roos, Y. B.W.E.M. (2008). Statin Treatment and the Occurrence of Hemorrhagic Stroke in Patients With a History of Cerebrovascular Disease. Stroke 39: 497-502 [Abstract] [Full Text]  
• Kinlay, S., Schwartz, G. G., Olsson, A. G., Rifai, N., Szarek, M., Waters, D. D., Libby, P., Ganz, P., for the Myocardial Ischemia Reduction with Aggress, (2008). Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study. Arterioscler. Thromb. Vasc. Bio. 28: 142-147 [Abstract] [Full Text]  
• (2007). Correction: Update in General Internal Medicine. ANN INTERN MED 147: 818-818 [Full Text]  
• Arboix, A, Font, A, Garro, C, Garcia-Eroles, L, Comes, E, Massons, J (2007). Recurrent lacunar infarction following a previous lacunar stroke: a clinical study of 122 patients. J. Neurol. Neurosurg. Psychiatry 78: 1392-1394 [Abstract] [Full Text]  
• Air, E. L., Kissela, B. M. (2007). Diabetes, the Metabolic Syndrome, and Ischemic Stroke: Epidemiology and possible mechanisms. Diabetes Care 30: 3131-3140 [Full Text]  
• Amarenco, P., Goldstein, L. B., Szarek, M., Sillesen, H., Rudolph, A. E., Callahan, A. III, Hennerici, M., Simunovic, L., Zivin, J. A., Welch, K. M. A., on behalf of the SPARCL Investigators, (2007). Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke 38: 3198-3204 [Abstract] [Full Text]  
• Henyan, N. N, Riche, D. M, East, H. E, Gann, P. N (2007). Impact of Statins on Risk of Stroke: A Meta-Analysis. The Annals of Pharmacotherapy 41: 1937-1945 [Abstract] [Full Text]  
• Chaturvedi, S., Turan, T. N., Lynn, M. J., Kasner, S. E., Romano, J., Cotsonis, G., Frankel, M., Chimowitz, M. I., For the WASID Study Group, (2007). Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology 69: 2063-2068 [Abstract] [Full Text]  
• Zhang, L., Zhang, Z. G., Liu, X. S., Hozeska-Solgot, A., Chopp, M. (2007). The PI3K/Akt Pathway Mediates the Neuroprotective Effect of Atorvastatin in Extending Thrombolytic Therapy After Embolic Stroke in the Rat. Arterioscler. Thromb. Vasc. Bio. 27: 2470-2475 [Abstract] [Full Text]  
• Vos, E., de Groot, P., Goldstein, L. (2007). Low LDL cholesterol, statins, and brain hemorrhage: Should we worry?. Neurology 69: 1469-1470 [Full Text]  
• Samuelson, R. M., Yamamoto, J., Levy, E. I., Siddiqui, A. H., Hopkins, L. N. (2007). The Argument to Support Broader Application of Extracranial Carotid Artery Stent Technology. Circulation 116: 1602-1610 [Full Text]  
• Touze, E., Varenne, O., Mas, J.-L. (2007). Overestimation of Coronary Risk in Stroke Patients. Stroke 38: e98-e98 [Full Text]  
• Colivicchi, F., Bassi, A., Santini, M., Caltagirone, C. (2007). Discontinuation of Statin Therapy and Clinical Outcome After Ischemic Stroke. Stroke 38: 2652-2657 [Abstract] [Full Text]  
• Sturgeon, J. D., Folsom, A. R., Longstreth, W.T. Jr, Shahar, E., Rosamond, W. D., Cushman, M. (2007). Risk Factors for Intracerebral Hemorrhage in a Pooled Prospective Study. Stroke 38: 2718-2725 [Abstract] [Full Text]